Clinical Trial Update: ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod [Phase 2]

View source ↗

Summary

Phase 2 trial ADAPT Forward 1 evaluating Empasiprubart IV as add-on therapy to Efgartigimod IV in AChR-Ab seropositive generalized Myasthenia Gravis with partia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Myasthenia Gravis
• Myasthenia Gravis

Drugs mentioned

• Efgartigimod IV (efgartigimod alfa)
• Empasiprubart IV (Empasiprubart)

Snippet

Sponsor: argenx | Conditions: AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis | Phase 2 | Status: RECRUITING